Lisinopril/HCTZ — $0 on Listed Strengths

About Lisinopril/HCTZ

Lisinopril HCTZ is a widely prescribed medication, combining two powerful agents to effectively manage high blood pressure. For many, the cost of essential medications can be a significant barrier. TheDrugClub is dedicated to making vital prescriptions like Lisinopril HCTZ accessible and affordable, ensuring our members can prioritize their health without financial stress.

High blood pressure, or hypertension, is a silent threat affecting millions. Left untreated, it can lead to serious health complications like heart attack, stroke, and kidney disease. Lisinopril HCTZ is a popular and effective combination medication designed to tackle this condition head-on.

What Lisinopril HCTZ Treats

This medication is primarily prescribed to treat essential hypertension, meaning high blood pressure with no identifiable cause. By combining two different types of blood pressure-lowering drugs, it offers a comprehensive approach to managing your cardiovascular health.

How It Works: A Synergistic Approach

Lisinopril HCTZ works by utilizing two distinct mechanisms:

1. Lisinopril (an ACE Inhibitor): This component works by blocking a substance in your body that narrows blood vessels. By relaxing the blood vessels, lisinopril allows blood to flow more easily, which in turn lowers blood pressure and reduces the workload on your heart. 2. Hydrochlorothiazide (a Diuretic): Often called a "water pill," hydrochlorothiazide helps your body get rid of excess salt and water. This reduces the total volume of fluid in your bloodstream, further contributing to lower blood pressure. The combination of these two agents often provides a more significant blood pressure reduction than

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Lisinopril/HCTZ is approved for (FDA label)

Lisinopril and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals.

Source: Read the full FDA label on DailyMed. Label effective date: December 3, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Lisinopril/HCTZ (FDA label)

WARNING: FETAL TOXICITY • When pregnancy is detected, discontinue lisinopril and hydrochlorothiazide tablets as soon as possible. • Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. See Warnings, Fetal Toxicity.

Source: FDA prescribing information (DailyMed). Set ID: 4510c108-2683-f505-e063-6394a90ab0a4. SPL document ID: 4510c108-2684-f505-e063-6394a90ab0a4. Label effective date: December 3, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Lisinopril/HCTZ (FDA label)

Lisinopril and hydrochlorothiazide tablets have been evaluated for safety in 930 patients, including 100 patients treated for 50 weeks or more. In clinical trials with lisinopril and hydrochlorothiazide tablets no adverse experiences peculiar to this combination drug have been observed. Adverse experiences that have occurred have been limited to those that have been previously reported with lisinopril or hydrochlorothiazide. The most frequent clinical adverse experiences in controlled trials (including open label extensions) with any combination of lisinopril and hydrochlorothiazide tablets were: dizziness (7.5%), headache (5.2%), cough (3.9%), fatigue (3.7%) and orthostatic effects (3.2%) all of which were more common than in placebo-treated patients.

Source: FDA prescribing information (DailyMed). Set ID: 4510c108-2683-f505-e063-6394a90ab0a4. SPL document ID: 4510c108-2684-f505-e063-6394a90ab0a4. Label effective date: December 3, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Lisinopril/HCTZ (FDA label)

Lisinopril and hydrochlorothiazide tablets are contraindicated in patients who are hypersensitive to any component of this product and in patients with a history of angioedema related to previous treatment with an angiotensin converting enzyme inhibitor and in patients with hereditary or idiopathic angioedema. Because of the hydrochlorothiazide component, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs. Lisinopril and hydrochlorothiazide tablets are contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer lisinopril and hydrochlorothiazide tablets within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see WARNINGS). Do not coadminister aliskiren with lisinopril and hydrochlorothiazide tablets in patients with diabetes.

Source: FDA prescribing information (DailyMed). Set ID: 4510c108-2683-f505-e063-6394a90ab0a4. SPL document ID: 4510c108-2684-f505-e063-6394a90ab0a4. Label effective date: December 3, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.